The application for the long-acting HIV therapy by Gilead (GILD.US) is about to be submitted.
Gilead Sciences (GILD.US) today announced the full results of the second pivotal Phase 3 trial PURPOSE 2 for lenacapavir, an investigational long-acting HIV-1 capsid inhibitor administered once every six months for HIV prevention.
Express News | Gilead Sciences Inc - Notes Include $750 Mln 4.80% Maturing 2029, $1 Bln 5.10% Maturing 2035
Gilead Prices $3.5 Billion of Senior Unsecured Notes
Citi Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $125
Express News | Citigroup initiates coverage on gilead sciences with a buy rating and a target price of $125.
Gilead Sciences' (NASDAQ:GILD) Soft Earnings Are Actually Better Than They Appear